Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
Healio19h
FDA recap: First new treatment for stroke in 3 decades, generic rivaroxaban and more
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
Precision Medicine Online20h
New Treatments Spur Interest in Broader Genetic Screening for Rare Heart Condition
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.
The Pharma Letter22h
BridgeBio’s Beyonttra approved in Japan
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...